Summary
Drug failure and high development cost (est. €2.3bn/new drug) have driven enormous growth in market need for scientific tests and disease models that narrow the gap between bench and clinic. This will be achieved by increasing the physiological relevance of the models used...
More information & hyperlinks
Web resources: | https://www.agilent.com/en/metacell |